The Ibogaine Story — Chapter 15: Molliver's Travels
Mechanisms Qualitative high
AI-extracted · unverified · confirm at source
1993 FDA Advisory Panel: Molliver-Mash confrontation over cerebellar toxicity (rats vs primates). Purkinje cell excitotoxicity, vincristine comparison, REM-reset hypothesis. ACT UP organising.
Dosing: 100 mg/kg sub-lethal in rats (~80% LD50); 25 mg/kg minimal toxicity in rats; 16–18 mg/kg estimated standard human dose; FDA-approved trial doses 1, 2, and 5 mg/kg (oral)
Contraindications: Cerebellar Purkinje cell loss at sub-lethal doses in rats (100 mg/kg = 10-15% loss; 25 mg/kg = <1%), Trunkal ataxia during treatment (vestibular disruption via vermis excitation), Potential thalamic and locus coeruleus secondary excitotoxicity at high doses